Carisma Therapeutics (CARM) to Release Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is expected to be posting its quarterly earnings results before the market opens on Monday, March 31st. Analysts expect Carisma Therapeutics to post earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Trading Down 7.8 %

NASDAQ CARM opened at $0.33 on Friday. Carisma Therapeutics has a twelve month low of $0.33 and a twelve month high of $2.30. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market cap of $13.78 million, a price-to-earnings ratio of -0.21 and a beta of 1.55. The firm’s 50 day moving average price is $0.44 and its two-hundred day moving average price is $0.67.

Analyst Upgrades and Downgrades

CARM has been the topic of several research analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a research note on Monday, January 13th. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Evercore ISI reissued an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. Finally, HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Carisma Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.